Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

Publication | Closed Access

DOI

Citations

References

2015

Year

Sylvie Lorenzen, Jorge Riera Knorrenschild, Georg-Martin Haag, Michael Pohl, Peter Thuss‐Patience, Florian Bassermann, Ulrike Helbig, Florian Weißinger, Elisabeth Schnoy, Gertraud Stocker,

European Journal of Cancer

Second-line TreatmentArbeitsgemeinschaft Internistische OnkologieGastrointestinal OncologyMedicinePharmacologyPathologyCancer TreatmentOncologyRadiation OncologyCancer ResearchLapatinib Versus Lapatinib